Mario Alberto Garza-Elizondo

Mario Alberto Garza-Elizondo

Auto-generated profile, based on publicly available information

Mario Alberto Garza-Elizondo

Rheumatology, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León (UANL), Monterrey, México

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
LLLuis Iván Lozano-Plata
Luis Iván Lozano-Plata
DVDavid Vega-Morales
David Vega-Morales
JEJorge Antonio Esquivel-Valerio
Jorge Antonio Esquivel-Valerio
MGMario Alberto Garza-Elizondo
Mario Alberto Garza-Elizondo
DGDionicio A. Galarza-Delgado
Dionicio A. Galarza-Delgado
RRRaúl Díaz-Niño de Rivera
Raúl Díaz-Niño de Rivera

14 March 2015 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
LPL. Pérez-Barbosa
L. Pérez-Barbosa
JEJ. A. Esquivel-Valerio
J. A. Esquivel-Valerio
AAA. C. Arana-Guajardo
A. C. Arana-Guajardo
DVDavid Vega-Morales
David Vega-Morales
JRJ. Riega-Torres
J. Riega-Torres
MGM. A. Garza-Elizondo
M. A. Garza-Elizondo

1 July 2015 in Reumatología Clínica
Verified
Journal Article
Closed access
AHAlexia Estefanía Hernández-Cáceres
Alexia Estefanía Hernández-Cáceres
JRJacqueline Rodriguez-Amado
Jacqueline Rodriguez-Amado
IPIngris Peláez-Ballestas
Ingris Peláez-Ballestas
DVDavid Vega-Morales
David Vega-Morales
MGMario Alberto Garza-Elizondo
Mario Alberto Garza-Elizondo

11 June 2010
Verified
Journal Article
Closed access
JEJorge Esquivel-Valerio
Jorge Esquivel-Valerio
LFLuis Felipe Flores-Suárez
Luis Felipe Flores-Suárez
JRJacqueline Rodríguez-Amado
Jacqueline Rodríguez-Amado
MGMario Alberto Garza-Elizondo
Mario Alberto Garza-Elizondo
ARAdrián Rendón
Adrián Rendón
MSMario C Salinas-Carmona
Mario C Salinas-Carmona

1 January 2017 in Reumatología Clínica (English Edition)
Verified
Journal Article
Closed access
NTNina Tello-Winniczuk
Nina Tello-Winniczuk
DVDavid Vega-Morales
David Vega-Morales
PGPedro A. García-Hernandez
Pedro A. García-Hernandez
JEJorge A. Esquivel-Valerio
Jorge A. Esquivel-Valerio
MGMario A. Garza-Elizondo
Mario A. Garza-Elizondo
AAAna C. Arana-Guajardo
Ana C. Arana-Guajardo

31 August 2021 in Modern Rheumatology
Verified
Journal Article
Open access
DVDavid Vega-Morales
David Vega-Morales
MGMario A Garza-Elizondo
Mario A Garza-Elizondo
LTLeendert A Trouw
Leendert A Trouw
KGKarina I Gonzalez-Torres
Karina I Gonzalez-Torres
ETErnesto Torres-Lopez
Ernesto Torres-Lopez
DGDionicio A Galarza-Delgado
Dionicio A Galarza-Delgado
Objectives: We aimed to determine the prevalence of anti-carbamylated protein (anti-CarP) antibodies in Mexican Hispanics with established rheumatoid arthritis (RA) and to assess their relationship with disease activity. Methods: A cohort study was conducted in 278 patients with established RA during an 18-month follow-up. We measured IgG/IgM/IgA rheumatoid factor (RF), IgG anticitrullinated protein antibodies (ACPA) and IgG/IgM/IgA anti-CarP antibodies using enzyme-linked immunosorbent assay (ELISA). For disease activity, we performed the 28-joint disease activity score with erythrocyte sedimentation rate (DAS28-ESR). Repeated measures one-way ANOVA was used to test the association between anti-CarP IgG antibody status and longitudinal DAS28-ESR scores. Patients were evaluated at baseline and at 6, 12, and 18 months during follow-up. Results: Anti-CarP IgG antibodies were positive in 47.8% of patients and, accounting for all isotypes, in 9.5% of patients with negative RF and ACPA. Triple antibody positivity was present in 42.6% of patients in our sample. Anti-CarP IgG antibody positivity did not show statistically significant differences in mean DAS28-ESR when compared to anti-CarP IgG antibody negative patients at baseline, 6, 12 or 18 months. Conclusion: Anti-CarP IgG antibodies are not associated to a higher disease activity in Hispanic patients with established RA. Our findings suggest that the clinical value of measuring anti-CarP antibodies in RA diminishes over time.